Bausch + Lomb progresses dry eye candidate to Phase III despite mixed data

Phase 3Positive

AI Analysis

Summary

Bausch + Lomb is advancing two candidates to Phase III development for dry eye and ocular pain despite mixed Phase II data. The progression indicates the company believes the candidates warrant further clinical evaluation despite early efficacy concerns.

Clinical Trial Data

Phase

Phase 3

Outcome Details

mixed Phase II data but progressing to Phase III

Importance:6/10

Sentiment:

0.30

dry eye diseaseocular painPhase 3 progressionophthalmology

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on August 25, 2026 3:29 PM

Read Original